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Abstract
Glucocorticoids (GCs) are a cornerstone in the treatment of lymphoid malignancies such as
multiple myeloma (MM) and acute lymphoblastic leukemia (ALL). Yet, prolonged GC use is
hampered by deleterious GC-related side effects and the emergence of GC resistance. To
tackle and overcome these GC-related problems, the applicability of selective glucocorticoid
receptor agonists and modulators was studied, in search of fewer side-effects and at least
equal therapeutic efficacy as classic GCs. Compound A (CpdA) is a prototypical example of
such a selective glucocorticoid receptor modulator and does not support GR-mediated
transactivation. Here, we examined whether the combination of CpdA with the classic GC
dexamethasone (Dex) may improve GC responsiveness of MM and ALL cell lines. We find
that the combination of Dex and CpdA does not substantially enhance GC-mediated cell kill-
ing. In line, several apoptosis hallmarks, such as caspase 3/7 activity, PARP cleavage and
the levels of cleaved-caspase 3 remain unchanged upon combining Dex with CpdA. More-
over, we monitor no additional inhibition of cell proliferation and the homologous downregu-
lation of GR is not counteracted by the combination of Dex and CpdA. In addition, CpdA is
unable to modulate Dex-liganded GR transactivation and transrepression, yet, Dex-medi-
ated transrepression is also aberrant in these lymphoid cell lines. Together, transrepres-
sion-favoring compounds, alone or combined with GCs, do not seem a valid strategy in the
treatment of lymphoid malignancies.
Introduction
Endogenous glucocorticoids (GCs), e.g. cortisol in humans, are stress-stimulated steroidal hor-
mones that modulate metabolism, inflammation, development, reproduction and the immune
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system [1,2]. Therapeutically, exogenous GCs, e.g. dexamethasone (Dex), are mostly used to
treat inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease,
asthma and atopic dermatitis [3]. In addition, GCs are deployed in cancer, either as adjuvant
(e.g. breast cancer) or as anti-cancer therapy (e.g. multiple myeloma) [4]. As co-medication,
GCs reduce edema, nausea and vomiting, avoid uncontrolled immune reactions caused by
chemotherapeutics and alleviate pain [5]. In lymphoid malignancies, such as multiple mye-
loma (MM) [6] and acute lymphoblastic leukemia (ALL) [7], GCs induce apoptosis of the
malignant cells [5,8].
At the molecular level, GCs bind to the glucocorticoid receptor (GR), a transcription factor
and nuclear receptor. GR’s genomic mechanisms have long been divided into two main
modes, i.e. transactivation, which promotes the transcription of glucocorticoid responsive
element (GRE)-driven genes (e.g. GILZ), and transrepression, via which GR inhibits the
expression of genes mediated by transcription factors such as NF-κB and AP-1 [9]. Yet, the
underlying interaction modes of GR with DNA, as a monomer or dimer, and with other tran-
scription factors, remain a subject of discussion [10,11]. Non-genomic mechanisms include,
among other mechanisms, translocation of GR into mitochondria, and was shown to correlate
with sensitivity of thymocytes to GC-mediated apoptosis [12,13].
Unfortunately, chronic administration of GCs is associated with deleterious side effects,
including diabetes, osteoporosis, muscle wasting and mood swings, and severely hampers the
quality of life of patients [14,15]. Prolonged GC treatment also leads to the emergence of GC
resistance, a condition in which the therapeutic effects are halted, but the side effects are largely
maintained [3,16,17], and of which the underlying mechanisms are diverse and incompletely
resolved [8,15,18–21].
In this context, a series of selective GR agonists and modulators (SEGRAMs) were devel-
oped, with a more specific action radius compared to classics GCs and which favor transre-
pression over transactivation [15,22]. The development of SEGRAMs was instigated by the
idea that most GC-related side effects arise from transactivation and that the anti-inflamma-
tory properties are largely coupled to transrepression [23]. However, this dissociation needs
to be nuanced, as transactivation of anti-inflammatory genes, e.g. SPHK1, was shown to be
important in combatting acute lung inflammation [24], and since GC-related osteoporosis not
solely results from GR transactivation but also from transrepression mechanisms [15,25].
Compound A (CpdA), a stable analogue of the plant-derived aziridine precursor found in a
Namibian shrub [26], is the prototypical example of a SEGRM with a completely dissociated
profile, that only supports transrepression and does not enhance transcription of GRE-driven
genes [27–29]. CpdA has been successfully applied in vivo improving the disease parameters in
mouse models of different inflammatory disorders [27,30–35]. CpdA was also shown to have
anti-cancer properties, as it induced apoptosis in prostate, bladder, leukemia and multiple
myeloma cells [4,28,36–39]. Recently, our group demonstrated in A549 cells that CpdA could
modulate Dex-bound GR by enhancing both anti-inflammatory GRE-driven gene expression
and the suppression of pro-inflammatory gene expression [29]. Moreover, in contrast to classic
GCs, prolonged CpdA treatment does not induce homologous downregulation of GR in
human synovial fibroblasts [16] and human leukemia and lymphoma cell lines [39].
As GR-mediated transrepression is an important mechanism in GC-induced cell killing, i.e.
by inhibiting the expression of several anti-apoptotic genes [5], we investigate whether com-
bining Dex with transrepression-favoring CpdA can enhance GC-mediated apoptosis. We also
explore whether CpdA can protect GR protein levels from Dex-instigated homologous down-
regulation, which could, in extension, prolong GC responsiveness of lymphoid malignant
cells.
Dex and CpdA combination in lymphoid malignancies
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Materials and methods
Cell lines and reagents
MM1.S, MM1.R, CEM-C7-14 and CEM-C1-15 cells were cultured in RPMI1640 GlutaMAX
(Gibco, life technologies), supplemented with 10% fetal calf serum (Greiner bio-one), 100U/ml
penicillin and 0.1mg/ml streptomycin (Gibco, life technologies), and grown in a 5% CO2
incubator at 37˚C. MM1.S, MM1.R were purchased from ATCC, CEM-C7-14 (C7-14) and
CEM-C1-15 (C1-15) cells were a kind gift from Prof. Brad E. Thompson (University of Texas
Medical branch). All experiments were performed using charcoal-stripped serum (Gibco, life
technologies). All cell lines were regularly tested for mycoplasma contamination and were
negative.
Dexamethasone (Dex) was purchased from Sigma Aldrich, dissolved in ethanol (EtOH)
and stored at -20˚C. Compound A (CpdA) was synthesized as described by Louw et al.[26],
dissolved in EtOH, flushed with an inert gas (N2-vapours), protected from light and was stored
at -80˚C. Recombinant murine TNFα, obtained from the VIB protein service facility, was dis-
solved in cell culture medium and used at a final concentration of 2000IU/ml. The total solvent
concentration in all experiments was kept equal in each condition.
RT-qPCR
Total RNA was isolated using an RNeasy mini kit (Qiagen), according to the manufacturer’s
instructions. The resulting RNA concentration was measured using a Biodrop (Isogen).
Reverse transcription (RT) was performed using an iScript cDNA synthesis kit (Bio-Rad). The
resulting cDNA was used as a template for quantitative PCR (qPCR) reactions using the Light-
cycler 480 SYBR Green I Master mix (Roche diagnostics), following the manufacturer’s proto-
col. The qPCR reaction protocol includes: a) activation enzyme and initial denaturation, 5’ at
95˚C; b) 40 cycles of denaturation 15” at 95˚C, hybridization and elongation 45” at 60˚C, and
was performed on a Lightcycler 480 system (384-well plate format, Roche diagnostics). The
primer sequences are available in S1 Table. Each condition was performed in triplicate and the
resulting Cq values were analyzed using qBasePlus (Biogazelle) and normalized to the refer-
ence genes: SDHA, RPL13A and YWHAZ [40,41]. Statistical analyses were performed on log
transformed data.
Protein lysates and Western blotting (WB)
Protein lysates were prepared using Totex lysis buffer (Hepes/KOH pH = 7.9 20mM, NaCl
350mM, glycerol 20%, NP-40 1%, MgCl2 1mM, EDTA 0.5mM, EGTA 0.1mM) freshly supple-
mented with Halt protease and phosphatase inhibitor cocktail, EDTA-free (Thermo scientific).
The samples’ protein concentration was measured via the Lowry method using the DC protein
assay (Bio-Rad). 25μg (or less) of total protein was denatured, loaded on a SDS-PAGE gel, and
blotted on a nitrocellulose membrane (Bio-Rad), followed by standard antibody probing pro-
cedures (Santa Cruz Biotechnology).
As primary antibodies, we used anti-GR (H300) (cat nr: sc-8992, Santa Cruz Biotechnol-
ogy), anti-PARP (cat nr: 556494, BD Biosciences), anti-cleaved caspase 3 (cat nr: 9664, Cell
Signaling), anti-GAPDH (cat nr: ab9485, Abcam), anti-GAPDH (cat nr: G8795, Sigma), and
anti-tubulin (cat nr: T5168, Sigma). The latter three antibodies were used as loading controls.
As secondary antibodies, we used species-specific HRP-conjugated antibodies (cat nr: NA931,
NA934, GE-Healthcare). To visualize results, Pierce ECL (Thermo Fisher Scientific), Wester-
nbright Quantum or Sirus (Isogen) served as chemiluminescent substrates and signals were
Dex and CpdA combination in lymphoid malignancies
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developed using X-Ray films (GE healthcare) or imaged on a ProXima 2850 imaging system
(Isogen).
Nucleus-cytoplasm fractionation
After washing the cells with ice-cold PBS, the cells were lysed in hypotonic buffer (20mM
HEPES pH = 7.0, 20% glycerol, 10mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.1% TritonX100,
supplemented with Halt protease and phosphatase inhibitor cocktail, EDTA-free (Thermo sci-
entific)) and centrifuged for 10min at 4˚C and 80rcf, separating the cytoplasmic from the
nuclear fraction. Next, the pelleted nuclei were resuspended in hypertonic buffer (hypotonic
buffer supplemented with 500mM NaCl) to disrupt the nuclear membrane and rotated for
30min at 4˚C, followed by centrifugation for 5min at 4˚C and 21130rcf. From each fraction,
the protein concentration was determined and maximally 10μg of total protein was further
processed for WB analysis.
MTT assay
After 72h of treatment (see figure legends), MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-
2H-tetrazolium bromide, Sigma-Aldrich, 5mg MTT/ml PBS) solution (40μl/well) was added
to the cells and incubated for 3-4h in a 37˚C incubator protected from light, giving rise to
insoluble (purple) formazan crystals in living cells. Next, SDS-HCl (10% SDS, 0.01M HCl) was
added to solubilize the crystals (100μl/well) and the plate was incubated overnight at room
temperature, protected from light and without a plate lid to allow equal evaporation. Absor-
bance (570nm with 650nm background correction) was measured using a Spectramax Para-
digm spectrophotometer (Beckman Coulter) with SoftMaxPro 6.1 software.
CellTiter-Glo and Caspase-Glo 3/7 assays
After 72h of treatment (see figure legends), cells were subjected to a CellTiter-Glo cell viability
or a Caspase-Glo 3/7 assay (Promega). The CellTiter-Glo or Caspase-Glo 3/7 reagent was
reconstituted by adding the CellTiter-Glo or Caspase_Glo 3/7 substrate to the CellTiter-Glo or
Caspase_Glo 3/7 buffer, respectively, and was equilibrated at room temperature. A volume of
CellTiter-Glo or Caspase_Glo 3/7 reagent equal to the volume in the well was added. The con-
tents were mixed on an orbital shaker to induce cell lysis and the plate was incubated for 10’
(CellTiter-Glo) or 1h (Caspase_Glo 3/7) to stabilize the luminescent signal. Luminescence was
recorded using a Spectramax Paradigm spectrophotometer (Beckman Coulter) with SoftMax-
Pro 6.1 software.
Cell proliferation assay
At the indicated time points, cells were stained with trypan blue (1:1 ratio with cells) and
counted using the Countess automated cell counter (Invitrogen).
Statistical analyses
Results are presented as scatter, dot or bar plots, in which the mean +/- standard error of the
mean (SEM) are depicted. When scatter dot plots are used, the open circles (o) represent the
mean of the individual biological replicates. Statistical analyses were performed using Graph-
Pad Prism 7 software. When the means of 2 groups were compared, a two-tailed unpaired t-
test was used. When the means of 2 variables (e.g. induction and concentration) of more than
2 groups were compared, a two-way ANOVA with Tukey’s or Sidak’s multiple comparisons
Dex and CpdA combination in lymphoid malignancies
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post-test was used. Results were designated significant when the P-value (P)< 0.05:  =
P< 0.05,  = P< 0.01,  = P< 0.001,  = P< 0.0001, ns = non-significant.
Results
CpdA does not support nuclear accumulation of GR yet induces HSP70
gene expression
CpdA was shown to induce nuclear translocation of GR in different cell models, albeit to vary-
ing degrees [27,28,42]. Therefore, we first assayed nuclear accumulation of GR upon CpdA
treatment in GC-sensitive MM1.S cells. We monitored the degree of cellular fractionation by
determining PARP and tubulin levels, as controls for nuclear and cytoplasmic fractions,
respectively (Fig 1A). As a positive control, Dex is used as it strongly induces nuclear transloca-
tion of GR [43]. In contrast, Fig 1A shows that CpdA does not support a marked nuclear accu-
mulation of GR.
Recently, Beck et al. reported that CpdA induces Hsp70 gene expression in A549 cells in a
GR-dependent manner [44]. Hence, as a control for the activity of CpdA, we monitored the
expression levels of HSPA1A, one of the genes coding for Hsp70 [45], in MM1.S after 6h treat-
ment with CpdA. As shown in Fig 1B, CpdA strongly induces HSPA1A expression compared
to solvent control.
Adding CpdA to Dex treatment does not substantially enhance GC-
mediated cell killing
Next, we determined GC responsiveness of the GC-sensitive MM1.S (MM) and C7-14 (ALL)
cells and the GC-resistant MM1.R (MM) and C1-15 cells (ALL) [46,47]. We treated these cells
for 72h with a concentration range (10-4M-10-10M) of Dex, CpdA or the combination hereof
and measured cell viability using MTT assays. Fig 2A and 2B show that the cell viability of GC-
sensitive MM1.S and C7-14 cells decreases with Dex treatments in a concentration-responsive
manner. As expected, GC-resistant MM1.R and C1-15 do not respond to Dex treatment (Fig
2C and 2D). In addition, CpdA alone does not decrease the cell viability of GC-sensitive MM1.
S and C7-14 cells (Fig 2A and 2B), except slightly (10–20%) at 10-6M in MM1.S and MM1.R
cells and in all cell lines at the higher (10-4M and 10-5M) concentrations. This mild effect of
Fig 1. CpdA does not support GR nuclear accumulation yet induces HSP70 gene expression in MM1.S cells. (A)
MM1.S cells were treated for 2h with Dex (10-6M) or CpdA (5.10-6M) and Nucleus (N)–Cytoplasm (C) fractionation
was performed. Protein lysates were prepared and WB analysis was performed, detecting the protein levels of GR (90-
95kDa) and PARP (89 and 113 kDa, N fraction control), with tubulin (55kDa, C fraction control) serving as loading
control. WB results are representative of 2 independent experiments. (B) MM1.S cells were treated for 6h with CpdA
(10-5M). RNA was isolated and subjected to RT-QPCR, detecting the mRNA levels of HSPA1A with SDHA, YWHAZ
and RPL13A serving as reference genes. The bar plot represents the mean +/- SEM of 5 biological replicates. A two-
tailed unpaired t-test was performed on log transformed data using GraphPad Prism 7.  = P< 0.001.
https://doi.org/10.1371/journal.pone.0197000.g001
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10-6M CpdA on cell viability seems GR-independent as it occurred in both GR-positive MM1.
S cells and in GR-negative MM1.R cells. Also, cell killing mediated by the highest CpdA con-
centrations (10-4M, 10-5M) is likely due to GR-independent effects, as it is also observed in the
GC-resistant, GR-positive C1-15 cells as well as in the GR-negative MM1.R cells (Fig 2C and
2D). The combination of Dex and CpdA shows a similar concentration-responsive reduction
of MM1.S and C7-14 cell viabilities as Dex treatment alone. Alternatively, cell viability was
determined using CellTiter-Glo assays and a similar concentration range (10-5M-10-9M) of
Dex, CpdA and the combination hereof. In accordance with the MTT results, addition of
CpdA to Dex treatment does not further decrease the cell viability of GC-sensitive MM and
ALL cells (S1 Fig).
In addition, this experiment was repeated with a fixed (lower) concentration of CpdA
(10-6M) and varying concentrations (10-5M-10-9M) of Dex. Fig 2E shows that combined Dex
and CpdA treatments leads to a minor reduction (on average 10%) of MM1.S cell viability at
each concentration, yet, overall no statistical interaction can be shown between Dex and
CpdA.
Dex and CpdA combination neither augments GC-induced apoptosis nor
increases cell proliferation inhibition
We further zoomed in on GC-mediated apoptosis and evaluated whether 72h treatment with a
limited concentration range (10-6M-10-8M) of Dex, CpdA or the combination of both could
increase caspase 3/7 activity of GC-sensitive MM1.S and C7-14 cells. Fig 3A and 3B shows that
Fig 2. Adding CpdA to Dex treatment does not substantially enhance GC-induced cell killing in GC-sensitive and GC-resistant MM and ALL cells. (A) MM1.S
and (B) C7-14 cells, (C) MM1.R and (D) C1-15 cells were treated for 72h with a concentration range (10-4M-10-10M) of Dex, CpdA or Dex/CpdA combinations
(equimolar concentrations). Cell viability was determined using MTT assays. (E) MM1.S cells were treated for 72h with fixed concentration CpdA (10-6M) and/or with
a concentration range (10-5M-10-9M) of Dex. Cell viability was determined using a CellTiter-Glo assay. The cell viability of the solvent control (EtOH) was set at 100%
and all other cell viabilities were normalized accordingly. The scatter plots represent the mean +/- SEM of 4 independent experiments. Statistical analysis was
performed using GraphPad Prism 7, using a two-way ANOVA with Tukey’s (A-D) or Sidak’s (E) multiple comparison post-test, comparing Dex vs. CpdA or Dex vs.
Dex/CpdA per concentration. Only significant differences are displayed:  = P< 0.05,  = P< 0.01,  = P< 0.001,  = P< 0.0001.
https://doi.org/10.1371/journal.pone.0197000.g002
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Dex treatment elevates the caspase 3/7 activity in MM1.S and C7-14 cells with increasing con-
centrations. Yet, maximal caspase 3/7 activity in C7-14 cells is reached at lower concentration
Dex (10-7M) compared to MM1.S cells (10-6M). CpdA treatment does not augment caspase 3/
7 activity at any concentration in C7-14 cells, while in MM1.S cells this activity is slightly
enhanced at 10-6M CpdA (Fig 3A and 3B). Equimolar Dex and CpdA combination also do not
augment caspase 3/7 activity compared to Dex treatment in MM1.S or C7-14 cells. In addition,
we repeated this experiment with a fixed concentration of CpdA (10-5M) and varying concen-
trations (10-6M-10-8M) of Dex. S2 Fig shows that 10-5M CpdA induces no caspase 3/7 activity
at 72h and is probably even cell-toxic, as the caspase 3/7 activity drops markedly under that of
the EtOH control in each condition where CpdA is added, an observation in line with Fig 2. In
contrast, at 24h and 48h of treatment, 10-5M CpdA induces cleavage of PARP and caspase 3
(apoptosis hallmarks) in MM1.S cells, yet, not at 10-6M and 10-7M CpdA. Also, at 48h, 10-5M
CpdA becomes cytotoxic for the cells as evidenced by the decreased GAPDH levels.
Protein levels of other apoptosis hallmarks, such as PARP cleavage and cleaved-caspase 3,
were also assayed following 72h treatment with Dex (10-6M or 5.10-8M), CpdA (5.10-6M) or a
combination thereof. CpdA treatment alone does not change the cleaved-caspase 3 levels, and
PARP cleavage is not induced in both MM1.S and C7-14 cells (Fig 3C and 3D). Cleaved-cas-
pase 3 levels are the highest and PARP cleavage is the strongest with 10-6M Dex treatment and
Fig 3. Adding CpdA to Dex treatment neither increases GC-induced apoptosis nor additionally inhibits cell proliferation of GC-sensitive MM and ALL cells.
(A) MM1.S and (B) C7-14 cells were treated for 72h with a concentration range (10-6M-10-8M) of Dex, CpdA or Dex/CpdA combinations (equimolar concentrations).
Caspase activity was determined using Caspase-Glo 3/7 assays. The caspase 3/7 activity of the solvent control (EtOH) was set at 1 and all other values were normalized
accordingly. The scatter plots represent the mean +/- SEM of 4 (A) or 3 (B) independent experiments. Statistical analysis was performed using GraphPad Prism 7,
using a two-way ANOVA with Tukey’s multiple comparison post-test, comparing Dex vs. CpdA or vs. Dex/CpdA per concentration. Only significant differences are
displayed:  = P< 0.01,  = P< 0.0001. (C) MM1.S and (D) C7-14 cells were treated for 72h with Dex (10-6M or 5.10-8M), CpdA (5.10-6M) or Dex/CpdA
combination. Protein lysates were prepared and subjected to WB analysis, assaying protein levels of cleaved caspase 3 (17 and 19 kDa), PARP (89 and 113kDa), with
GAPDH (37kDa) serving as loading control. WB results are representative of 2 independent experiments. (E) MM1.S and (F) C7-14 cells were treated for 24h, 48h or
72h with Dex (10-6M), CpdA (5.10-6M) or Dex/CpdA combination. At the corresponding time points, the cells were stained with trypan blue and counted using the
Countess automated cell counter. The bar plots represent the mean +/- SEM of 3 independent experiments. Statistical analysis was performed using GraphPad Prism 7,
using a two-way ANOVA with Tukey’s multiple comparison post-test. Only significant differences are displayed:  = P< 0.05,  = P< 0.01,  = P< 0.001,  =
P< 0.0001.
https://doi.org/10.1371/journal.pone.0197000.g003
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added CpdA does not change these levels (Fig 3C and 3D), possibly because a plateau is
reached. In line with this hypothesis, combining 5.10-8M Dex with CpdA increases the levels
of cleaved-caspase 3 compared to 5.10-8M Dex alone in both cell lines, yet, this is not the case
for PARP cleavage (Fig 3C and 3D).
In addition, cell proliferation was assayed by treating MM1.S and C7-14 cells for 72h with
Dex (10-6M), CpdA (5.10-6M) or both combined. As expected, the number of living cells
increases in the control condition in function of time, indicative of proliferating cells (Fig 3E
and 3F). In contrast, Dex treatment blocks proliferation of the cells, which is most pronounced
at 72h in C7-14 cells. CpdA does not affect cell proliferation as the number of living cells/ml is
comparable to the control condition. Consistently, Fig 3E and 3F show that the combination
of Dex and CpdA largely reflects the number of living cells/ml of Dex treatment alone.
GR protein levels are not sustained by combining Dex and CpdA
CpdA was previously shown to protect GR from homologous downregulation in various cells
[16,39]. Therefore, we wondered whether the addition of CpdA to Dex treatment might sus-
tain GR protein levels in MM1.S, C7-14 and C1-15 cells. To this end, cells were treated for 72h
with a concentration range (10-5M-10-9M) of Dex, CpdA or a combination hereof (Fig 4A),
and GR protein levels were determined. MM1.R cells are not taken along as they are GR-nega-
tive (S3A Fig). GR levels in GC-resistant C1-15 cells remain largely unaltered, regardless of
any treatment (Fig 4A and 4B). In MM1.S and C7-14 cells, GR protein levels decrease by Dex
treatment in a concentration-responsive manner, except in C7-14 cells at 10-8M Dex, where
GR levels even increase compared to control. Although this 10-8M Dex-effect is already present
after 24h, the increase in GR levels is most pronounced after 72h (S3B Fig). CpdA treatment
alone does not affect GR protein levels, but again kills cells at 10-5M in MM1.S cells, as evident
from the lacking GAPDH levels (Fig 4A). Equimolar concentrations of CpdA and Dex is
unable to rescue GR from degradation in MM1.S and C7-14 cells, and GR levels largely resem-
ble those of Dex treatment alone.
To exclude that the latter is due to the use of equimolar concentrations, we treated the cells
with a fixed CpdA concentration on top of varying Dex concentrations (10-6M-10-9M). Fig 4B
shows that using this treatment scheme, GR protein levels are also not protected from degrada-
tion and are strongly reduced in a concentration-dependent manner compared to control.
Fig 4. GR protein levels are not preserved by combining Dex with CpdA in GC-sensitive MM and ALL cells, or in GC-resistant ALL cells. MM1.S, C7-14 and C1-
15 cells were treated for 72h with (A) a concentration range (10-5M-10-9M) of Dex, CpdA or Dex/CpdA combination or (B) a concentration range of Dex (10-6M-
10-9M), CpdA (5.10-6M) or Dex/CpdA combination. Protein lysates were prepared and WB analysis was performed, detecting the protein levels of GR (90-95kDa),
with GAPDH (37kDa) serving as a loading control. WB results are representative of 3 independent experiments.
https://doi.org/10.1371/journal.pone.0197000.g004
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CpdA does not alter Dex-mediated transactivation of GRE-driven genes
Our group recently reported that CpdA can modulate Dex-instigated gene expression [29]. To
test whether this also occurs in lymphoid cell lines, cells were treated for 6h with Dex, CpdA or
the combination hereof, followed by QPCR analyses of GR and of its target genes GILZ and
FKBP5. Both GILZ and FKBP5 are strongly induced upon Dex treatment in MM1.S and C7-
14 cells (Fig 5) but also in C1-15 cells (S4A Fig), the latter regardless of the cells’ resistance
towards GC-mediated apoptosis. GR mRNA levels are unaffected by 6h Dex treatment in
MM1.S cells, but are upregulated in C7-14 and C1-15 cells (Fig 5 and S4A Fig). At large, CpdA
does not support transactivation of GRE-driven genes, except for a mild increase in GILZ
expression in MM1.S cells (Fig 5A). Moreover, combining Dex and CpdA does not alter the
expression levels of these genes compared to Dex treatment (Fig 5), except for the GR mRNA
levels in C1-15 cells, which are elevated compared to Dex (S4A Fig).
CpdA does not support transrepression of pro-inflammatory genes, in
presence or absence of Dex
We subsequently wondered whether CpdA supports transrepression in the lymphoid cell lines
under study and whether CpdA modulates transrepression instigated by Dex-activated GR.
Hence, we prestimulated the cells 1h with Dex, CpdA or a combination thereof, followed or
not by 5h of a pro-inflammatory stimulus (TNFα) and assayed the mRNA levels of A20,
NFKBIA (IκBα), ICAM and RANTES.
A20 and NFKBIA, both key inhibitors of NF-κB, are induced upon TNFα stimulation and
both have a GR- and NF-κB-binding site in their corresponding promoters [48,49] (Fig 6).
Dex augments NFKBIA expression levels in MM1.S and C7-14 cells, and only in the latter even
beyond the TNFα-induced NFKBIA expression (Fig 6, S4B Fig). TNFα-induced A20mRNA
Fig 5. CpdA does not modulate Dex-induced GR transactivation of GRE-driven genes in GC-sensitive MM and
ALL cells. (A) MM1.S and (B) C7-14 cells were treated for 6h with Dex (10-6M), CpdA (10-5M) or Dex/CpdA
combination. RNA was isolated and subjected to RT-QPCR, detecting the mRNA levels of GILZ, FKBP5 and GR and
with SDHA, YWHAZ and RPL13A serving as reference genes. The dot plots represent the mean +/- SEM of 5 biological
replicates, with the open circles (o) representing the mean of each biological experiment. A two-way ANOVA with
Tukey’s multiple comparison post-test was performed on log transformed data using GraphPad Prism 7.  = P< 0.01,
 = P< 0.0001, ns = non-significant.
https://doi.org/10.1371/journal.pone.0197000.g005
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expression is not further induced by Dex. Moreover, CpdA does not significantly decrease
TNFα-stimulated A20 or NFKBIA mRNA levels in any cell line. Also, the combination of Dex
and CpdA does not differentially affect the TNFα-induced expression of A20 and NFKBIA
compared to Dex treatment (Fig 6, S4B Fig).
The pro-inflammatory genes ICAM and RANTES are upregulated by TNFα treatment,
while Dex only mildly reduces this stimulation for RANTES in MM1.S cells (Fig 6A). Remark-
ably, in MM1.S cells CpdA stimulates ICAM expression in the absence of TNF, albeit mildly.
Nevertheless, in all cell lines, CpdA is unable to significantly reduce TNFα-stimulated expres-
sion of ICAM and RANTES and also the combination of Dex and CpdA does not result in fur-
ther inhibition of TNFα-induced pro-inflammatory gene expression compared to Dex (Fig 6,
S4B Fig).
Discussion
The potential of SEGRAMs to reduce the number and intensity of GC-coupled side effects
with improved therapeutic efficacy and prolonged responsiveness [3,15], is an attractive route
to explore in lymphoid malignancies. Therefore, we investigated whether the combination of
classic GCs with transrepression-favoring SEGRAMs could promote GC-induced apoptosis
and/or postpone GC resistance by protecting GR from degradation.
CpdA did not substantially induce GRE-driven gene expression in MM1.S, C7-14 or C1-15
cells, in accordance with previous reports on other cell types [27,28,30,50]. The lack of CpdA
to induce GR dimerization was proposed to underlie its dissociated behavior [30,42] and was
also linked to decreased nuclear import and increased nuclear export [51]. In line herewith,
Fig 6. CpdA does not transrepress pro-inflammatory genes in GC-sensitive MM and ALL cells, in absence or presence of Dex. (A) MM1.S and (B) C7-14 cells
were pretreated with Dex (10-6M), CpdA (10-5M) or Dex/CpdA combination for 1h, followed by or not treatment with TNFα (2000IU/ml) for another 5h. RNA was
isolated and subjected to RT-QPCR, detecting the mRNA levels of A20,NFKBIA, ICAM and RANTES, with SDHA, YWHAZ and RPL13A serving as reference genes.
The dot plots represent the mean +/- SEM of 3 biological replicates, with the open circles (o) representing the mean of each biological experiment. A two-way ANOVA
with Tukey’s multiple comparison post-test was performed on log transformed data using GraphPad Prism 7.  = P< 0.05,  = P< 0.01, ns = non-significant.
https://doi.org/10.1371/journal.pone.0197000.g006
Dex and CpdA combination in lymphoid malignancies
PLOS ONE | https://doi.org/10.1371/journal.pone.0197000 May 8, 2018 10 / 17
CpdA indeed did not lead to a marked GR nuclear enrichment in MM1.S cells. Varying
degrees of CpdA-instigated GR nuclear translocation were also reported in LNCaP-GR pros-
tate cancer cells [28], CT5.3hTERT cancer-associated fibroblasts [52] and A549 cells [29], and
thus seems a cell type-dependent phenomenon. In addition, CpdA’s dissociated behavior
could arise from a different conformational change in GR, leading to altered coregulator
recruitment and slightly altered target gene preferences [27,29,53,54]. Consistent herewith,
CpdA increased GILZ and ICAM expression in MM1.S and C7-14 cells, respectively. Alterna-
tively, CpdA is able to GR-independently upregulate DUSP1 in airway smooth muscle cells as
part of a mechanism by which CpdA blocks production of GC-resistant chemokines [55]. Sim-
ilarly, Desmet et al. observed a CpdA-mediated upregulation of DUSP1 in intestinal epithelial
cells and to a lesser extent in A549 cells [29]. In addition, HSPA1A mRNA was upregulated by
CpdA in MM1.S cells, which was also reported for A549 cells, albeit as a GR-dependent phe-
nomenon [44]. The fact that DNA itself can act as a sequence-specific allosteric regulator
of GR [56], might be an additional contributor as to why certain GR ligands discriminate
between GR transactivation of particular genes. Principally, CpdA could not modulate Dex-
induced transactivation, except for an increased GR expression in C1-15 cells, as compared to
Dex, again suggesting cell type- and gene-specific modulation.
TNF-induced pro-inflammatory gene expression was only modestly reduced by Dex in
MM1.S cells and additional CpdA did not alter these Dex effects. Also CpdA alone failed
to inhibit TNF-induced pro-inflammatory gene expression. This aberrant transrepression pro-
file on top of a lack in transactivation may underpin why adding CpdA to Dex treatment
largely failed to enhance GC-mediated apoptosis and to additionally inhibit cell proliferation
of these lymphoid cell lines. The actual mechanisms underlying GC-induced apoptosis in lym-
phoid cells are not completely elucidated [4,57]. For instance, there is no consensus whether
either transactivation of pro-apoptotic genes (e.g. BIM, GILZ), or the transrepression of pro-
inflammatory genes (e.g. IL-6), anti-apoptotic genes (e.g. Bcl-XL) and cell cycle promoting
genes (e.g. cyclin D1), is the most crucial mechanism governing GC-induced apoptosis
[8,18,19,21,58,59]. It is most likely that both mechanisms contribute to GC-mediated cell
death and that also non-genomic mechanisms are important [12]. Anyhow, we found that
GC-induced killing of lymphoid cells was only slightly strengthened by adding (10-6M) CpdA
and given its dissociated profile, this suggests that transrepression alone is most likely not suffi-
cient to provoke GC-mediated apoptosis. In addition, CpdA alone has two different effects
depending on the concentration that is used: 10-4M-10-5M CpdA (high concentration) is cyto-
toxic, while 10-6M CpdA and lower concentrations are not. These results differ from the stud-
ies of Lesovaya and coworkers, showing CpdA induced PARP cleavage and upregulated Bim
and p53 expression in leukemia cells [38], with nanomolar amounts of CpdA able to reduce
the cell growth of MM1.S cells [39]. However, in the same study CpdA also reduced the cell
growth of GR-negative MM1.R cells at 10-7M [39], indicating that the observed results might
have a GR-independent component.
In contrast, we only observed massive cell death with CpdA at very high concentrations
(10-4M-10-5M), which was independent of the cells’ GR status and responsiveness to GCs. This
agrees with Wu¨st and colleagues, who showed that various cell types (lymphocytes, fibroblasts,
neuronal cells) can undergo massive GR-independent cell death with high dose CpdA [31].
This is ascribed to CpdA’s instability and thus its cyclization into an aziridine intermediate,
which is known to have alkylating properties. This process especially occurs in buffers (e.g.
PBS at higher pH) and after longer incubation periods [31]. However, this does not mean that
in another study CpdA’s effects are also per se GR-independent, as this most definitely also
depends on the cell context (e.g. inflammation vs. cancer) and cell type.
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Prolonged treatment with CpdA was shown to protect GR from homologous downregula-
tion in fibroblast-like synoviocytes, isolated from rheumatoid arthritis patients. Treatment for
24h with CpdA sustained GR protein levels, while Dex already downregulated GR levels after
6h [16]. CpdA treatment of CEM and NCEB cells for 24h also preserved GR levels [39]. In con-
trast, here, addition of CpdA to Dex treatment was unable to prevent homologous downregu-
lation of GR in lymphoid cell lines. The proposed combination strategy is thus unable to
prolong GC responsiveness in lymphoid cell lines via sustained and protected GR protein
levels.
Besides in lymphoid malignancies, CpdA was also described to have anti-cancer properties
in solid cancers [4]. In prostate cancer, CpdA was shown to act as a combined AR antagonist
and GR agonist, resulting in the inhibition of prostate tumor growth and the induction of apo-
ptosis in vitro [28]. The latter effect was even more pronounced when CpdA was combined
with Bortezomib, as this proteasome inhibitor results in GR accumulation [36]. Also in blad-
der cancer, CpdA was reported to inhibit cell proliferation and induce cell cycle arrest and
apoptosis in GR+/AR+ cells, and to reduce tumor growth more strongly than Dex in a xeno-
graft model [37]. In addition, Chen and coworkers demonstrated that in triple negative breast
cancer (TNBC), where GCs are given as adjuvant, CpdA regulates only a small number of
genes that are not involved in carcinogenesis. This is in sharp contrast to Dex, which regulates
a large set of genes that are associated with TNBC progression and drug resistance [60]. The
latter exemplifies the potential for SEGRAMs in solid tumors.
Taken together, we favor CpdA’s classification as a selective GR modulator (not ligand),
which refers to its dissociated behavior, meaning that CpdA supports GR transrepression but
not GR transactivation. Yet, this terminology does not exclude alternative action modes of
CpdA such as non-genomic mechanisms, or targeting of other nuclear receptors or transcrip-
tion factors. Finally, our study demonstrates that dissociated, transrepression-favoring com-
pounds, such as CpdA, do not seem a valid therapeutic strategy in the treatment of lymphoid
malignancies, but can hold promise for the treatment of solid cancers and inflammation.
Supporting information
S1 Table. RT-qPCR primer sequences.
(DOCX)
S1 Fig. Effect of Dex, CpdA and Dex/CpdA combination treatment on the cell viability of
GC-sensitive MM and ALL cells. (A) MM1.S (MM) and (B) C7-14 (ALL) cells were treated
for 72h with a concentration range (10-5M-10-9M) of Dex, CpdA or Dex/CpdA combination
(equimolar concentrations). The cell viability was determined using CellTiter-Glo assays. The
cell viability of the solvent control (EtOH) was set at 100% and all other cell viabilities were
normalized accordingly. The scatter plots represent the mean +/- SEM of 3 independent exper-
iments. Statistical analysis was performed using GraphPad Prism 7, using a two-way ANOVA
with Tukey’s multiple comparison post-test, comparing Dex vs. CpdA or vs. Dex/CpdA per
concentration. Only significant differences are displayed:  = P< 0.05,  = P< 0.01,  =
P< 0.0001.
(TIF)
S2 Fig. Effect of Dex, CpdA and Dex/CpdA combination treatment on GC-induced apo-
ptosis of GC-sensitive MM and ALL cells. (A) MM1.S and (B) C7-14 cells were treated for
72h with a Dex concentration range (10-6M-10-8M), CpdA (10μM) or Dex/CpdA combination
(fixed CpdA concentration). The caspase activity was determined using Caspase-Glo 3/7
assays. The caspase 3/7 activity of the solvent control (EtOH) was set at 1 and all other values
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were normalized accordingly. The scatter plots represent the mean +/- SEM of 3 independent
experiments. Statistical analysis was performed using GraphPad Prism 7, using a two-way
ANOVA with Sidak’s multiple comparison post-test, comparing Dex vs. Dex/CpdA per con-
centration. Only significant differences are displayed:  = P< 0.01. (C) MM1.S cells were
treated for 24h or 48h with solvent, 10-6M Dex or a limited CpdA concentration range (10-5M-
10-7M). Protein lysates were subjected to WB analysis, determining the protein levels of PARP
(89 and 113kDa) and cleaved-caspase 3 (17-19kDa), with GAPDH (37kDa) serving as loading
control. Results are representative of 3 independent experiments.
(TIF)
S3 Fig. Absence of GR in MM1.R cells and Dex concentration range of C7-14 cells in func-
tion of time. (A) MM1.R cells were treated for 72h with a Dex concentration range (10-4M-
10-10M). (B) C7-14 cells were treated for 24h, 48h or 72h with a Dex concentration range
(10-7M-10-9M). (A-B) Protein lysates were prepared and WB analysis was performed, detect-
ing the protein levels of GR (90-95kDa), with GAPDH (37kDa) serving as loading control. WB
results arise from 1 (A) biological experiment, or are representative of 2 (B) biological experi-
ments.
(TIF)
S4 Fig. Evaluation of transactivation and transrepression in GC-resistant ALL cells. C1-15
cells were treated for 6h with Dex (1μM), CpdA (10μM) or Dex/CpdA combination. RNA was
isolated and subjected to RT-QPCR, detecting the mRNA levels of (A) GILZ, FKBP5 and GR as
a measure for transactivation and (B) A20, NFKBIA, ICAM and RANTES as a measure for
transrepression. (A-B) SDHA, YWHAZ and RPL13A served as reference genes. The dot plots
represent the mean +/- SEM of 5 (A) or 3 (B) biological replicates with the open circles (o) rep-
resenting the mean of each biological experiment. A two-way ANOVA with Tukey’s multiple
comparison post-test was performed on log transformed data using GraphPad Prism 7.  =
P< 0.05,  = P< 0.01,  = P< 0.0001, ns = non-significant.
(TIF)
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